Phase II Study of Interleukin 6 Blockade With Siltuximab to Decrease Symptom Burden in Patients Age 60-75 Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma and AL Amyloidosis

Trial Profile

Phase II Study of Interleukin 6 Blockade With Siltuximab to Decrease Symptom Burden in Patients Age 60-75 Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma and AL Amyloidosis

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs Siltuximab (Primary)
  • Indications Amyloid light-chain amyloidosis; Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Nov 2017 Planned initiation date changed from 1 Oct 2017 to 1 Nov 2017.
    • 26 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top